Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma

Simple Summary The prognosis of ovarian clear cell carcinoma was poor due to chemoresistance; therefore, immunotherapy, such as the glypican-3 (GPC3) peptide vaccine, gained attraction, as it prolonged survival. There were some super responders; however, response rates were limited because of the lack of predictive biomarkers for the efficacy of treatment. The purpose of this study was to explore circulating biomarkers using pre-treatment serum samples from a GPC3 peptide vaccine clinical trial in order to predict response to vaccine therapy. We identified serum miR-375-3p, miR-193a-5p, and miR-1228-5p as predictive biomarkers of response to GPC3 peptide vaccine therapy. These miRNAs were not overexpressed in tumor tissues, and functional annotation analysis suggested that these miRNAs were associated with interferon-related pathways. Therefore, these biomarkers may reflect the immune activity of patients and may have broader applications in all immune-related therapies, including tumor vaccines. Abstract Ovarian clear cell carcinoma (OCCC) has been treated with surgery and chemotherapy; however, the prognosis remains poor because of chemoresistance. Therefore, immunotherapies are attracting attention, including the GPC3 peptide vaccine, which improves overall survival. However, the response rate is limited and there are no sufficient predictive biomarkers that can identify responders before treatment. Our purpose was to identify circulating serum miRNAs as predictive biomarkers for response to GPC3 peptide vaccine. Eighty-four patients in a phase II trial of a GPC3 peptide vaccine were enrolled and miRNA sequencing was performed on their serum samples. Candidate miRNAs were selected from a group of 14 patients for whom treatment was responsive and validated in an independent group of 10 patients for whom treatment was responsive. Three markedly upregulated miRNAs, miR-375-3p, miR-193a-5p, and miR-1228-5p, were identified, and the combination of those miRNAs demonstrated high value in the prediction of the response. The origin of these miRNAs was assessed by referring to OCCC tissue miRNA profiles, and they were not identified as cancer tissue-related miRNAs. Functional annotation analysis suggested that they were associated with interferon-related pathways. The miRNAs identified herein have great potential to allow the realization of liquid biopsy for predicting the immunotherapy response and precision medicine.

[1]  T. Ochiya,et al.  The clinical impact of intra‐ and extracellular miRNAs in ovarian cancer , 2020, Cancer science.

[2]  Rui Li,et al.  Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis , 2020, BioMed research international.

[3]  P. Benedetti Panici,et al.  Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches , 2020, OncoTargets and therapy.

[4]  Mingliang Ye,et al.  MicroRNA‐375‐3p enhances chemosensitivity to 5‐fluorouracil by targeting thymidylate synthase in colorectal cancer , 2020, Cancer science.

[5]  Yu-qin Pan,et al.  miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells , 2019, Aging.

[6]  R. López-López,et al.  Circulating microRNAs as Promising Biomarkers in Colorectal Cancer , 2019, Cancers.

[7]  T. Ochiya,et al.  Integrated extracellular microRNA profiling for ovarian cancer screening , 2018, Nature Communications.

[8]  B. Nelson,et al.  Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study , 2018, Oncoimmunology.

[9]  F. Sánchez‐Madrid,et al.  Control of Immunoregulatory Molecules by miRNAs in T Cell Activation , 2018, Front. Immunol..

[10]  Yingying Zhao,et al.  miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling. , 2018, Oncology reports.

[11]  L. Kwong,et al.  Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy , 2017, Cancer and Metastasis Reviews.

[12]  Man-Li Zhang,et al.  Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel , 2017, Journal of experimental & clinical cancer research : CR.

[13]  A. Gadducci,et al.  Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. , 2017, Anticancer research.

[14]  Yusuke Nakamura,et al.  miR‐125b‐1 and miR‐378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer , 2017, Cancer science.

[15]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[16]  J. Madore,et al.  Tumor Suppressor microRNAs Contribute to the Regulation of PD‐L1 Expression in Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Wang-xian Tang,et al.  MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma , 2017, Molecular therapy. Nucleic acids.

[18]  K. Okuno,et al.  MicroRNA-6826 and −6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer , 2016, Oncology reports.

[19]  M. Nevalainen,et al.  miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1 , 2016, Molecular Cancer.

[20]  H. Kajiyama,et al.  Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma , 2016, Oncoimmunology.

[21]  G. Chiappetta,et al.  Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. , 2016, The Lancet. Oncology.

[22]  K. Fujiwara,et al.  Clear-cell carcinoma of the ovary. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Yong Li,et al.  Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 , 2016, Nature Communications.

[24]  Jingde Zhu,et al.  miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway , 2014, Molecular Cancer.

[25]  K. Miyazono,et al.  MicroRNA regulons in tumor microenvironment , 2014, Oncogene.

[26]  Lin Jiang,et al.  Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. , 2014, Gene.

[27]  F. Kikkawa,et al.  Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy , 2013, Human vaccines & immunotherapeutics.

[28]  C. Croce,et al.  MicroRNAs as therapeutic targets in chemoresistance. , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  Y Pawitan,et al.  Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.

[30]  A. Belldegrun,et al.  Dendritic Cell–Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM·CAIX in Immunocompetent Mouse Models , 2013, Journal of immunotherapy.

[31]  B. Goff.  Advanced ovarian cancer: what should be the standard of care? , 2013, Journal of gynecologic oncology.

[32]  Anton P. McCaffrey,et al.  Identifying Functional MicroRNAs in Macrophages with Polarized Phenotypes* , 2012, The Journal of Biological Chemistry.

[33]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[34]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[35]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[36]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[37]  Hiroshi I. Suzuki,et al.  miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. , 2011, Blood.

[38]  S. Tavazoie,et al.  A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells , 2011, Nature.

[39]  F. Kikkawa,et al.  Glypican‐3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma , 2011, Cancer science.

[40]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[41]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[42]  L. Kappos,et al.  Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients , 2010, European journal of immunology.

[43]  J. Fruehauf,et al.  Targeted Therapy in Ovarian Cancer , 2010, Journal of oncology.

[44]  V. Kim.  MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[45]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[46]  Kenichi Tanaka,et al.  Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. , 1991, Cancer research.

[47]  L. Brandes,et al.  IMMUNOTHERAPY FOR OVARIAN CANCER , 1976, The Lancet.